Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies

被引：22

作者：

Caso, Francesco ^{[2
,3
]}

Costa, Luisa ^{[2
,3
]}

Del Puente, Antonio ^{[3
]}

Di Minno, Matteo Nicola Dario ^{[5
]}

Lupoli, Gelsy ^{[4
]}

Scarpa, Raffaele ^{[3
]}

Peluso, Rosario ^{[1
]}

机构：

[1] Univ Naples Federico II, Rheumatol Res Unit, Dept Clin Med & Surg, I-80131 Naples, Italy

[2] Univ Padua, Dept Med DIMED, Rheumatol Unit, Padua, Italy

[3] Univ Naples Federico II, Rheumatol Unit, Dept Clin Med & Surg, I-80131 Naples, Italy

[4] Univ Naples Federico II, Dept Clin Med & Surg, I-80131 Naples, Italy

[5] IRCCS, Ctr Cardiol Monzino, Unit Cell & Mol Biol Cardiovasc Dis, Milan, Italy

来源：

THERAPEUTIC ADVANCES IN CHRONIC DISEASE | 2015年 / 6卷 / 06期

关键词：

biological therapies; nonsteroidal anti-inflammatory drugs; spondyloarthritis; ACTIVE ANKYLOSING-SPONDYLITIS; PLACEBO-CONTROLLED TRIAL; INFLAMMATORY-BOWEL-DISEASE; OPEN-LABEL TRIAL; ASAS/EULAR MANAGEMENT RECOMMENDATIONS; PSORIATIC-ARTHRITIS PATIENTS; NECROSIS-FACTOR BLOCKERS; FACTOR-ALPHA BLOCKERS; ANTI-TNF THERAPY; DOUBLE-BLIND;

D O I：

10.1177/2040622315608647

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Spondyloarthritis represents a heterogeneous group of articular inflammatory diseases that share common genetic, clinical and radiological features. The therapy target of spondyloarthritis relies mainly in improving patients' quality of life, controlling articular inflammation, preventing the structural joints damage and preserving the functional abilities, autonomy and social participation of patients. Among these, traditional disease-modifying antirheumatic drugs have been demonstrated to be effective in the management of peripheral arthritis; moreover, in the last decade, biological therapies have improved the approach to spondyloarthritis. In patients with axial spondyloarthritis, tumor necrosis factor a inhibitors are currently the only effective therapy in patients for whom conventional therapy with nonsteroidal anti-inflammatory drugs has failed. The aim of this review is to summarize the current experience and evidence about the pharmacological approach in spondyloarthritis

引用

页码：328 / 338

页数：11

共 104 条

[1] Tocilizumab in refractory Takayasu arteritis: A case series and updated literature review [J].

Abisror, Noemie ;

Mekinian, Arsene ;

Lavigne, Christian ;

Vandenhende, Marie-Anne ;

Soussan, Michael ;

Fain, Olivier .

AUTOIMMUNITY REVIEWS, 2013, 12 (12) :1143-1149

[2] Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review [J].

Acosta Felquer, Maria Laura ;

Coates, Laura C. ;

Soriano, Enrique R. ;

Ranza, Roberto ;

Espinoza, Luis R. ;

Helliwell, Philip S. ;

FitzGerald, Oliver ;

McHugh, Neil ;

Roussou, Euthalia ;

Mease, Philip J. .

JOURNAL OF RHEUMATOLOGY, 2014, 41 (11) :2277-2285

[3]

[Anonymous], COCHRANE DATABASE SY

[4] A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis [J].

Ash, Zoe ;

Gaujoux-Viala, Cecile ;

Gossec, Laure ;

Hensor, Elizabeth M. A. ;

FitzGerald, Oliver ;

Winthrop, Kevin ;

van der Heijde, Desiree ;

Emery, Paul ;

Smolen, Josef S. ;

Marzo-Ortega, Helena .

ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (03) :319-326

[5] The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection [J].

Atteno, Mariangela ;

Costa, Luisa ;

Matarese, Alessandro ;

Caso, Francesco ;

Del Puente, Antonio ;

Cantarini, Luca ;

Bocchino, Maria Luisa ;

Sanduzzi, Alessandro ;

Scarpa, Raffaele .

CLINICAL RHEUMATOLOGY, 2014, 33 (04) :543-547

[6] Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs [J].

Atteno, Mariangela ;

Peluso, Rosario ;

Costa, Luisa ;

Padula, Stefania ;

Iervolino, Salvatore ;

Caso, Francesco ;

Sanduzzi, Alessandro ;

Lubrano, Ennio ;

Del Puente, Antonio ;

Scarpa, Raffaele .

CLINICAL RHEUMATOLOGY, 2010, 29 (04) :399-403

[7] Immunogenicity and autoimmunity during anti-TNF therapy [J].

Atzeni, F. ;

Talotta, R. ;

Salaffi, F. ;

Cassinotti, A. ;

Varisco, V. ;

Battellino, M. ;

Ardizzone, S. ;

Pace, F. ;

Sarzi-Puttini, P. .

AUTOIMMUNITY REVIEWS, 2013, 12 (07) :703-708

[8] Rheumatic manifestations in inflammatory bowel disease [J].

Atzeni, Fabiola ;

Defendenti, Caterina ;

Ditto, Maria Chiara ;

Batticciotto, Alberto ;

Ventura, Donatella ;

Antivalle, Marco ;

Ardizzone, Sandro ;

Sarzi-Puttini, Piercarlo .

AUTOIMMUNITY REVIEWS, 2014, 13 (01) :20-23

[9] Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial [J].

Baeten, Dominique ;

Baraliakos, Xenofon ;

Braun, Juergen ;

Sieper, Joachim ;

Emery, Paul ;

van der Heijde, Desiree ;

McInnes, Iain ;

van Laar, Jacob M. ;

Landewe, Robert ;

Wordsworth, Paul ;

Wollenhaupt, Juergen ;

Kellner, Herbert ;

Paramarta, Jacqueline ;

Wei, Jiawei ;

Brachat, Arndt ;

Bek, Stephan ;

Laurent, Didier ;

Li, Yali ;

Wang, Ying A. ;

Bertolino, Arthur P. ;

Gsteiger, Sandro ;

Wright, Andrew M. ;

Hueber, Wolfgang .

LANCET, 2013, 382 (9906) :1705-1713

[10] Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis [J].

Baraliakos, Xenofon ;

van den Berg, Rosaline ;

Braun, Juergen ;

van der Heijde, Desiree .

RHEUMATOLOGY, 2012, 51 (08) :1378-1387

← 1 2 3 4 5 6 7 8 9 10 →